Wave Life Sciences Ltd.
Clinical trials sponsored by Wave Life Sciences Ltd., explained in plain language.
-
New Weight-Loss drug WVE-007 enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug, WVE-007, in 136 adults aged 18 to 60 who are overweight or have obesity (BMI 28-35). The main goal is to check the drug's safety and how the body processes it. Participants will receive either the drug or a placebo as a single injection, a…
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for duchenne: drug targets missing protein
Disease control Recruiting nowThis study tests a drug called WVE-N531 in people with Duchenne muscular dystrophy (DMD), a genetic condition that causes muscle weakness. The drug aims to help the body produce a protein called dystrophin, which is missing in DMD. About 26 participants will receive the drug thro…
Phase: PHASE1, PHASE2 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC